![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, et al. 2009. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 16:719–727.
- Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. 2018. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 26:603–610.
- Brinton LA, Felix AS. 2014. Menopausal hormone therapy and risk of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology 142:83–89.
- Bruyniks N, Biglia N, Palacios S, Mueck AO. 2017. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 20:195–204.
- Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. 2016. Therapeutic options for management of endometrial hyperplasia. Journal of Gynecologic Oncology 27:e8.
- Constantine GD, Graham S, Lapane K, Ohleth K, Bernick B, Liu J, et al. 2019. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause 26:800–807.
- Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. 2018. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 25:11–20.
- Gunnison KM, Tucker LY, Postlethwaite DA, Pruett KM. 2015. Topical vaginal estrogen use and risk of endometrial hyperplasia or cancer. Obstetrics & Gynecology 125:8S.
- Kagan R, Kellogg-Spadt S, Parish SJ. 2019. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs & Aging 36:897–908.
- Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. 2015. The recent review of the genitourinary syndrome of menopause. Journal of Menopausal Medicine 21:65–71.
- Kozma B, Póka R, Sipos A, Ács N, Takács P. 2019. Short-term efficacy of vaginal CO2 laser therapy as a treatment modality for genitourinary syndrome of menopause. Orvosi Hetilap 160:1617–1622.
- Medscape Medical News. 2019. Confusion as EU Advice on Vaginal Estradiol Differs from US. Medscape Medical News©. [cited 2019 Nov 15]. Available from: https://www.medscape.com/viewarticle/921389
- Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. 2014. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics and Gynecology 124:1147–1156.
- Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. 2010. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstetrics and Gynecology 116:876–883.
- Tempfer CB, Bentz EK, Leodolter S, Tscherne G, Reuss F, Cross HS, et al. 2007. Phytoestrogens in clinical practice: a review of the literature. Fertility and Sterility 87:1243–1249.
- Urbaniak GC, Plous S. 2013. Research Randomizer (version 4.0) [computer software]. [cited 2013 June 22]. Available from: http://www.randomizer.org/